Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ATYR

Atyr Pharma Inc

Mar 12 • 04:00PM ET

0.8675

-0.0544 -5.90 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN SRPT ALNY NBIX IONS FOLD BLUE PTCT CSL

| Held by: VTI IWM VXF IWO VTWO IWC ITOT VTWG RSSL IWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.80	Insider Own	2.50%	Shs Outstand	98.03M	Perf Week	-3.86%
Market Cap	85.06M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	68.16%	Shs Float	95.60M	Perf Month	-1.42%
Enterprise Value	18.21M	PEG	-	EPS next Q	-0.13	Inst Own	56.18%	Short Float	19.67%	Perf Quarter	7.32%
Income	-74.12M	P/S	447.68	EPS this Y	26.67%	Inst Trans	-6.96%	Short Ratio	9.44	Perf Half Y	-83.44%
Sales	0.19M	P/B	1.26	EPS next Y	29.69%	ROA	-77.12%	Short Interest	18.80M	Perf YTD	10.78%
Book/sh	0.69	P/C	1.08	EPS next 5Y	37.27%	ROE	-107.81%	52W High	7.29 -88.10%	Perf Year	-75.56%
Cash/sh	0.80	P/FCF	-	EPS past 3/5Y	20.65% 14.76%	ROIC	-94.97%	52W Low	0.64 35.55%	Perf 3Y	-55.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-73.65% -55.14%	Gross Margin	-717.37%	Volatility	7.45% 8.91%	Perf 5Y	-82.37%
Dividend TTM	-	EV/Sales	95.84	EPS Y/Y TTM	8.34%	Oper. Margin	-40856.32%	ATR (14)	0.08	Perf 10Y	-98.79%
Dividend Ex-Date	-	Quick Ratio	5.30	Sales Y/Y TTM	-19.15%	Profit Margin	-39009.47%	RSI (14)	45.53	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	5.30	EPS Q/Q	21.23%	SMA20	-9.10%	Beta	0.59	Target Price	4.36
Payout	-	Debt/Eq	0.18	Sales Q/Q	-	SMA50	2.11%	Rel Volume	0.59	Prev Close	0.92
Employees	58	LT Debt/Eq	0.16	Earnings	Mar 05 AMC	SMA200	-65.65%	Avg Volume	1.99M	Price	0.87
IPO	May 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.83% -100.00%	Trades		Volume	1,173,655	Change	-5.90%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-16-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$1.50
Sep-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$1
Sep-15-25	Downgrade	Leerink Partners	Outperform → Market Perform	$1
Sep-15-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-15-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-18-25	Initiated	Leerink Partners	Outperform	$16
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Oct-04-24	Initiated	Wells Fargo	Overweight	$17
Sep-05-24	Initiated	Jefferies	Buy	$9
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform	$22
Sep-21-21	Initiated	Piper Sandler	Overweight	$19
May-10-21	Initiated	Laidlaw	Buy	$18
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy	$13
Mar-04-20	Initiated	ROTH Capital	Buy	$15
Mar-02-20	Initiated	Oppenheimer	Outperform	$8
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight	$7
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral

Show Previous Ratings

Mar-05-26 04:10PM	Atyr Pharma: Q4 Earnings Snapshot (Associated Press Finance) -6.45% -8.68%
04:01PM	aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update (GlobeNewswire)
Feb-20-26 04:01PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-18-26 08:00AM	aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-03-26 08:00AM	aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis (GlobeNewswire)
04:08PM	Loading…
Nov-25-25 04:08PM	aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman (PR Newswire)
Nov-20-25 01:27PM	aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman (Newsfile)
Nov-18-25 02:03PM	ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman (PR Newswire)
Nov-11-25 09:23AM	aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman (PR Newswire)
Nov-10-25 08:00AM	aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 04:48PM	Atyr Pharma: Q3 Earnings Snapshot (Associated Press Finance) -5.35% +6.05%
04:01PM	aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update (GlobeNewswire)
08:35AM	Investors in aTyr Pharma, Inc. (ATYR): Protect Your Rights - Contact Levi & Korsinsky Before December 8, 2025 (Newsfile)
Oct-23-25 01:11PM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (Newsfile)
Oct-21-25 09:00AM	Shareholders of aTyr Pharma, Inc. Should Contact Levi & Korsinsky Before December 8, 2025 to Discuss Your Rights - ATYR (PR Newswire)
02:05PM	Loading…
Oct-15-25 02:05PM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (Business Wire)
Oct-14-25 08:20AM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (PR Newswire) +7.68%
Oct-10-25 07:06PM	aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ATYR (Business Wire) +11.23% -8.89%
Oct-09-25 10:18PM	aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman (PR Newswire)
Sep-30-25 05:30AM	aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 (GlobeNewswire) -9.28%
Sep-23-25 09:22AM	aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman (PR Newswire) -5.70%
Sep-17-25 09:03AM	aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens Berman (PR Newswire) -5.09%
Sep-16-25 07:20AM	aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail (Clinical Trials Arena) +6.40%
Sep-15-25 08:11AM	ATyr shares plunge on trial miss in inflammatory lung disease (BioPharma Dive) -83.17%
07:30AM	aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire)
Sep-11-25 10:15AM	1 Small-Cap Biotech Stock Poised for a Breakout (Motley Fool)
03:31AM	Lead Therapy Trial Fuels aTyr Pharma's (ATYR) Promising Upside, Leerink Stays Bullish (Insider Monkey)
Sep-08-25 12:30AM	Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results (Insider Monkey)
Sep-05-25 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.02%
12:22AM	Loading…
Aug-20-25 12:22AM	ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations (Insider Monkey) +5.58%
Aug-07-25 04:41PM	Atyr Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update (GlobeNewswire)
Jul-31-25 10:40AM	Martin Shkreli Is Shorting This Strong Buy Penny Stock. How Should You Play Shares Here? (Barchart)
Jul-22-25 08:00AM	aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis (GlobeNewswire) -8.23%
Jun-26-25 08:00AM	aTyr Pharma to be Added to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-04-25 08:00AM	aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (GlobeNewswire)
May-21-25 11:21AM	aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential (Insider Monkey) +7.45%
May-20-25 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-19-25 08:00AM	aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire) +5.20%
May-16-25 04:01PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.00%
May-14-25 08:00AM	aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis (GlobeNewswire) -8.46%
May-09-25 08:32AM	Is aTyr Pharma, Inc. (ATYR) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-07-25 04:01PM	aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update (GlobeNewswire) +5.70%
Apr-29-25 08:00AM	aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-03-25 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire) -5.74%
Mar-27-25 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
12:27PM	Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-26-25 08:00AM	aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise (GlobeNewswire) -7.16%
Mar-19-25 09:40AM	Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-14-25 03:11AM	aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Mar-13-25 04:01PM	aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update (GlobeNewswire) +12.39%
Mar-12-25 04:00PM	aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine (GlobeNewswire) +15.64%
Mar-06-25 04:02PM	aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) +10.39%
Mar-04-25 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results (GlobeNewswire) -8.18%
Feb-24-25 08:00AM	aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -11.34%
Jan-29-25 08:00AM	aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire)
Dec-17-24 08:00AM	aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 04:00PM	aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors (GlobeNewswire)
Dec-10-24 08:00AM	aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) -6.80%
Dec-09-24 08:00AM	aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis (GlobeNewswire) +5.06%
Nov-15-24 08:00AM	aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis (GlobeNewswire) -8.93%
Nov-07-24 04:01PM	aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update (GlobeNewswire)
Oct-31-24 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-14-24 08:00AM	aTyr Pharma to Present at the LD Micro Main Event XVII in October (Newsfile)
Oct-08-24 08:00AM	aTyr Pharma's Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting (GlobeNewswire)
Oct-02-24 08:00AM	aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal (GlobeNewswire)
Aug-21-24 08:00AM	aTyr Pharma to Participate in September Investor Conferences (GlobeNewswire)
Aug-13-24 04:00PM	aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update (GlobeNewswire) +6.32%
Aug-06-24 08:00AM	aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations (GlobeNewswire)
Jul-30-24 08:00AM	aTyr Pharma Announces Research Study with Stanford Medicine (GlobeNewswire) -6.60%
Jul-22-24 08:00AM	aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis (GlobeNewswire) +13.41%
Jun-18-24 09:40AM	Is aTyr Pharma (ATYR) Outperforming Other Medical Stocks This Year? (Zacks) -6.78%
Jun-10-24 10:52AM	ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023 (InvestorPlace)
Jun-05-24 03:17PM	Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 (InvestorPlace)
Jun-03-24 08:00AM	aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from LIFE to ATYR (GlobeNewswire) +6.94%
May-24-24 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-24 07:00AM	aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference (GlobeNewswire) +5.22%
May-14-24 08:00AM	aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary Sarcoidosis (GlobeNewswire) +7.06%
May-06-24 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-24 09:58PM	LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:15PM	Atyr Pharma: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update (GlobeNewswire)
Apr-01-24 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire)
Mar-26-24 02:19PM	3 Penny Stocks That Could Be Multibaggers in the Making: March Edition (InvestorPlace)
Mar-15-24 01:33PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript (Insider Monkey) +22.84%
11:30AM	Q4 2023 aTyr Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
11:01AM	aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress (GuruFocus.com)
Mar-14-24 08:56PM	LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023 (InvestorPlace)
04:16PM	Atyr Pharma: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update (GlobeNewswire)
Feb-28-24 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results (GlobeNewswire) -5.00%
Feb-21-24 08:00AM	aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT Clinical Trial Participants (GlobeNewswire)
Jan-29-24 08:00AM	aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity (GlobeNewswire)
Jan-18-24 08:00AM	aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor (GlobeNewswire)
Nov-13-23 08:00AM	aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023 (GlobeNewswire)
Nov-09-23 04:07PM	Atyr Pharma: Q3 Earnings Snapshot (Associated Press Finance) -5.74%
04:00PM	aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 08:00AM	aTyr Pharma to Present at November Investor Conferences (GlobeNewswire)
Oct-31-23 08:00AM	aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD (GlobeNewswire)

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shukla Sanjay	President and CEO	Feb 04 '26	Sale	0.98	3,745	3,655	153,553	Feb 04 07:17 PM
Broadfoot Jill Marie	Chief Financial Officer	Feb 04 '26	Sale	0.98	1,558	1,521	37,296	Feb 04 07:15 PM
DENYES NANCY	General Counsel	Feb 04 '26	Sale	0.98	1,118	1,091	33,124	Feb 04 07:12 PM
SCHIMMEL PAUL	Director	Oct 08 '25	Buy	0.90	682,001	612,437	1,095,024	Oct 09 06:30 PM
SCHIMMEL PAUL	Director	Oct 09 '25	Buy	0.94	317,999	299,364	1,413,023	Oct 09 06:30 PM
Gross Jane A	Director	Mar 17 '25	Buy	4.00	3,750	15,000	9,750	Mar 17 07:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATYR

Atyr Pharma Inc

Upgrade your FINVIZ experience